CAR T-cell therapy for liver cancer that has GPC3
Part of Cancer, Digestive system clinical trials.
This early-phase study tests modified immune T cells (CAR T cells) to treat hepatocellular carcinoma (HCC), a type of liver cancer, when the tumor shows a marker called GPC3. It may help shrink tumors or slow cancer growth, especially after other treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed liver cancer (HCC) by scan or pathology.
- Your tumor tests positive for GPC3 (from a biopsy or stored tumor tissue from the last year).
- Your liver cancer is not removable by surgery (BCLC stage B or C), and has gotten worse after standard treatments.
- You’ve already had at least two types of whole-body (systemic) cancer treatment, and the cancer kept growing during or after them.
- Your overall health is good enough for treatment (Child-Pugh A or B7, no past liver brain confusion, ECOG 0–1), and you have at least one measurable tumor spot.
- You must not have certain medical situations (brain/spinal spread, prior organ transplant, major immune/virus infections, or pregnancy/breastfeeding).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a personalized immune-cell treatment (CAR T cells) for advanced liver cancer that has the GPC3 protein. It aims to see whether these engineered cells can find and kill cancer cells safely and help shrink the cancer.
This trial tests a custom immune-cell treatment (CAR-T) that targets a marker called GPC3 in people with advanced hepatocellular carcinoma (a type of liver cancer). It’s for cases where standard treatments have not worked well, and the goal is to shrink tumors and improve outcomes.
This early-phase trial tests a personalized CAR-T cell treatment for cancers that make a lot of a protein called GPC3. If you have advanced cancer that has already tried at least one standard treatment, and your tumor has enough GPC3, this study aims to see how well the treatment can shrink tumors and how safe it is.
This study tests a new kind of immune therapy called CAR T-cells that are specially designed to find and attack cancer cells that carry a protein called GPC3. Researchers want to see if this treatment is safe and helpful for people with solid tumors that have not responded to standard therapies.
This trial tests a new type of immunotherapy called CAR T cells that are trained to find and attack cancer cells with a specific marker (GPC3). The CAR T cells are also 'armored' with extra proteins (IL-15 and IL-21) to help them work better. It might be an option for adults with advanced solid tumors, especially liver cancer, that have not responded to standard treatments.
This trial tests a custom immune-cell treatment made to target a marker (GPC3) found on some liver cancers. It’s for adults with advanced HCC whose cancer has worsened after standard treatment or who couldn’t tolerate it.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.